Karl-Heinz Klempnauer

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 5

Top Topics

Heat Shock Protein

Acute Myeloid Leukemia

Tyrosine Kinase

Top Venues

ACS medicinal chemistry letters

This page only lists publications with an associated author ORCID identifier.

Publications

Leonhard H F Köhler, Sebastian Reich, Maria Yusenko, Karl-Heinz Klempnauer, Amin H Shaikh, Khursheed Ahmed, Gerrit Begemann, Rainer Schobert, Bernhard Biersack
A New Naphthopyran Derivative Combines c -Myb Inhibition, Microtubule-Targeting Effects, and Antiangiogenic Properties. ACS medicinal chemistry letters 13 (11) (2022)
Jan Paul Müller, Karl-Heinz Klempnauer
The CDC37-HSP90 chaperone complex co-translationally degrades the nascent kinase-dead mutant of HIPK2. FEBS letters 595 (11) (2021)
Maria V Yusenko, Amke Trentmann, Debora A Casolari, Luca Abdel Ghani, Mairin Lenz, Melanie Horn, Wolfgang Dörner, Stefan Klempnauer, Henning D Mootz, Maria Francisca Arteaga, Jan-Henrik Mikesch, Richard J D'Andrea, Thomas J Gonda, Carsten Muller-Tidow, Thomas Jürgen Schmidt, Karl-Heinz Klempnauer
C/EBPβ is a MYB- and p300-cooperating pro-leukemogenic factor and promising drug target in acute myeloid leukemia. Oncogene 40 (29) (2021)
Eugen Werwein, Abhiruchi Biyanee, Karl-Heinz Klempnauer
Intramolecular interaction of B-MYB is regulated through Ser-577 phosphorylation. FEBS letters 594 (24) (2020)
Anna Coulibaly, Astrid Haas, Simone Steinmann, Anke Jakobs, Thomas J Schmidt, Karl-Heinz Klempnauer
The natural anti-tumor compound Celastrol targets a Myb-C/EBPβ-p300 transcriptional module implicated in myeloid gene expression. PloS one 13 (2) (2018)